Here we characterized this conformation using pure mouse MDR3 P-glycoprotein and natural MgATP and MgADP. Mutants E552A/E1197A, E552Q/E1197Q, E552D/ E1197D, and E552K/E1197K had low but real ATPase activity in the order Ala > Gln > Asp > Lys, emphasizing the requirement for Glu stereochemistry. Mutant E552A/ E1197A bound MgATP and MgADP (1 mol/mol) with K d 9.2 and 92 M, showed strong temperature sensitivity of MgATP binding and equal dissociation rates for MgATP and MgADP. With MgATP as the added ligand, 80% of bound nucleotide was in the form of ATP. None of these parameters was vanadate-sensitive. The other mutants showed lower stoichiometry of MgATP and MgADP binding, in the order Ala > Gln > Asp > Lys. We conclude that the E552A/E1197A mutation arrests the enzyme in a conformation, likely a stabilized NBD dimer, which occludes nucleotide, shows preferential binding of ATP, does not progress to a normal vanadate-sensitive transition state, but hydrolyzes ATP and releases ADP slowly. Impairment of turnover is primarily due to inability to form the normal transition state rather than to slow ADP release. The Gln, Asp, and Lys mutants are less effective at stabilizing the occluded nucleotide, putative dimeric NBD, conformation. We envisage that in wild-type the occluded nucleotide conformation occurs transiently after MgATP binds to both NBDs with associated dimerization, and before progression to the transition state.
the numerous compounds transported by Pgp, and there is the realization that a substantial number of future new drug candidates will similarly be transport substrates, so much current interest centers on strategies aimed at disabling or circumventing Pgp. Consisting of two transmembrane domains and two nucleotide binding domains (NBDs), Pgp displays the typical architecture of the ABC transporter family of membrane transporters. There is as yet no reported high resolution structure of Pgp, but structures of several homologous ABC transporters, and of isolated NBDs, have been published recently. For recent reviews of Pgp structure and function see Refs. 1-6. Our laboratory has focused on the mechanism of ATP hydrolysis and ATP hydrolysis-driven transport. Procedures for large scale preparation of pure human MDR1 (7) and mouse MDR3 2 protein (8) have recently facilitated such studies. Earlier work had established that Pgp showed drug-stimulated ATPase activity (9, 10) and that hydrolysis of ATP occurred in both NBDs (11) . It was clear from studies with inhibitors N-ethylmaleimide and 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (10, (12) (13) (14) , mutations in the catalytic sites (15, 16) , and vanadate-trapping experiments (17) that the two NBDs cooperated strongly and mandatorily for hydrolysis, and an alternating sites mechanism was proposed in 1995 (18) . This mechanism envisaged that formation of the chemical transition state required cooperation of both NBDs, and collapse of the transition state with P i release was geared to conformational changes at distant drug binding sites in the transmembrane domains, resulting in drug transport. Much subsequent work has supported this mechanism as a general framework, and extensions/modifications have been proposed (19, 20) .
A mutagenesis study (21) led to the proposal that cooperativity between the Pgp NBDs involved formation of a "closed" conformation in which "the two domains must come together to allow residues from one site to project into the other." It was suggested that the closed conformation was required after initial ATP binding to attain the transition state. Later work on formation of the transition state analog Pgp⅐MgADP⅐V i supported this proposal (22) as did cross-linking studies showing proximity (7) and likely interdigitation (23) of the Pgp NBDs. Studies with other ABC transporters have given structural backing to the concept. Thomas and colleagues (24) demonstrated ATP-dependent dimerization of isolated NBD subunits from two ABC transporters of Methanococcus jannaschi (called MJ0796 and MJ1267). Interestingly, dimer formation was not seen with wild-type subunits, which had robust ATPase activity, but only in mutants that had very low activity. The mutations were Glu to Gln or Glu to Ala at the conserved Glu residue, which lies immediately adjacent to and downstream from the Walker B Asp residue. Mutation of this Glu residue in Pgp (25) and other ABC transporters (26, 27) has been seen to impair ATP hydrolysis and it appears to function as a "catalytic carboxylate." 3 X-ray crystallography of the dimer formed by the mutant MJ0796 NBD subunits (29) revealed structural details demonstrating two NaATP molecules sandwiched at the dimer interface between the Walker A motif in one NBD subunit and the LSGGQ ABC transporter signature motif of the other. The mutated Glu residues are located at the dimer interface. ATPdependent dimer formation of the NBDs of a mitochondrial ABC transporter Mdl1p was also seen (26) using the parallel Glu to Gln mutant, and two nucleotides were bound tightly to the NBD dimer. Dimers of native MalK NBDs have been visualized by x-ray crystallography, with two ATP (without Mg 2ϩ ) bound at the dimer interface (30) . In this case a regulatory domain specific to MalK appears to facilitate maintenance of dimer structure.
The aforementioned studies were carried out on ABC transporters that contain identical NBD subunits, thus the Glu mutation was present in both NBDs. In Pgp the analogous situation would be combined mutation of the catalytic Glu in both NBDs. Two such mutants have been reported, namely the E556Q/E1201Q and E556A/E1201A mutants of human Pgp (28) . Using crude membranes and 8-azido-ATP as an analog of natural ATP, it was shown that these mutations changed the behavior of Pgp in an important way, namely that Pgp had gained the ability to bind nucleotide much more tightly than in wild-type. This work potentially opens up an avenue to studies of an intermediate conformational state in the Pgp mechanism, namely the closed dimer state with nucleotide bound.
In this work we present detailed characterization of this Pgp conformation. We have used pure mouse MDR3 protein, with natural substrates/products ATP and ADP to allow binding stoichiometries and binding parameters to be determined directly. Different mutations at the catalytic carboxylate residues (residues Glu-552 and Glu-1197 of mouse MDR3) were incorporated to compare their effects on ATPase activity and on generation and properties of the tight nucleotide binding conformation. [8] [9] [10] [11] [12] [13] [14] C]ADP and [␣-32 P]ATP were purchased from PerkinElmer Life Sciences. Escherichia coli lipids were purchased from Avanti Polar Lipids.
EXPERIMENTAL PROCEDURES

Materials
Construction of Mutant Pgp; Expression of Mutant Pgp in Pichia pastoris
Mutations at positions 552 and 1197 of mouse MDR3 Pgp were generated by PCR mutagenesis of pAlt-mdr3N and pAlt-mdr3.6C, respectively, as described previously (31) . The following mutant species were generated: E552Q/E1197Q, E552A/E1197A, E552D/E1197D, and E552K/E1197K. The mutagenic oligonucleotide pairs used were as follows: E552Q forward, 5Ј- CTTTTGTTGGACCAGGCCACGTCAGCC-3Ј  and E552Q reverse, 5Ј-CCAGGGCTGACGTGGCCTGGTCCAACAAAA-GG-3Ј; E552A forward, 5Ј-GTTGGACGCGGCCACGTCAGCC-3Ј and  E552A reverse, 5Ј-CCAGGGCTGACGTGGCCGCGTCCAACAAAAGG-3Ј; E552D forward, 5Ј-GTTGGACGATGCCACGTCAGCC-3Ј and E552D  reverse, 5Ј-CCAGGGCTGACGTGGCATCGTCCAACAAAAGG-3Ј;  E552K forward, 5Ј-GTTGGACAAGGCCACGTCAGCC-3Ј and E552K  reverse, CCAGGGCTGACGTGGCCTTGTCCAACAAAAGG-3Ј; E1197Q   forward, 5Ј-CTTCTGGACCAAGCAACATCAGCTCTG-3Ј and E1197Q  reverse, 5Ј-CAGAGCTGATGTTGCTTGGTCCAGAAG-3Ј; E1197A forward, 5Ј-CTTCTGGACGCAGCAACATCAGCTCTG-3Ј and E1197A reverse, 5Ј-CAGAGCTGATGTTGCTGCGTCCAGAAG-3Ј; E1197D forward, 5Ј-CTTCTGGACGATGCAACATCAGCTCTG-3Ј and E1197D reverse, 5Ј-CAGAGCTGATGTTGCATCGTCCAGAAG-3Ј; E1197K forward, 5Ј-CTTCTGGACAAAGCAACATCAGCTCTG-3Ј and E1197K reverse, 5Ј-CAGAGCTGATGTTGCTTTGTCCAGAAG-3Ј. Additional flanking primers used were: M13 forward, 5Ј-CGC-CAGGGTTTTCCCAGTCACGAC-3Ј and M13 reverse, 5Ј-AGCG-GATAACAATTTCACACAGGA-3Ј; and Sma forward, 5Ј-CTGGTTGGT-GAGAGAGGGGCG-3Ј. PCR products were initially cloned into SmaIlinearized pUC118 by blunt end ligation. The presence of desired mutations and absence of undesired base changes were confirmed by DNA sequencing. Mutations at position 552 or 1197 were then transferred into pHILD-mdr3.6-His 6 (21) on SmaI-EcoRI or SpeI-SnaBI fragments, respectively. Expression of mutant Pgp in the yeast P. pastoris was performed as described previously (8, 32) .
Purification and Quantitation of Pgp
Strains of P. pastoris expressing the mutant Pgp were grown in fermenter culture and purified as described (8, 21) . The Pgp concentration was determined as described previously (31) . Briefly, increasing amounts of mutant Pgp (0.2-2.0 g) were subjected to SDS-gel electrophoresis on 10% gels alongside a similar set of samples of a reference pure wild-type preparation whose concentration had previously been determined accurately by amino acid analysis. Gels were stained with Coomassie Blue and scanned. Protein bands were quantified with Scion Image software (Scion Corporation, Frederick, MD).
Activation of Pgp by Lipids and DTT; Centrifuge Column Elution of Pgp
For activation, Pgp was incubated with 8 mM DTT and E. coli lipid (Avanti, acetone/ether-precipitated) at a final ratio of 50:1 (for ATPase measurement) or 2:1 (for centrifuge column experiments) lipid/protein (w/w) for 20 min at room temperature followed by sonication for 30 s at 4°C in a bath sonicator (8) . Centrifuge column elution of Pgp was exactly as in Ref. 22 . Briefly, elution was at 4°C, using 1-ml Sephadex G-50 columns equilibrated in 50 mM Tris-Cl, pH 7.5, and 0.001% N-dodecyl-␤-D-maltoside. As noted in Ref. 22 and confirmed here, recovery of Pgp was routinely 70 -90% as judged by ATPase and/or protein assays. To reduce the amount of experimental manipulation to manageable proportions we routinely assumed a protein recovery of 80%.
Assay of ATPase Activity
Release of radioactive P i from [␥-32 P]ATP was determined using the charcoal adsorption assay as described previously (31) using 0.5-1 g of lipid-and DTT-activated Pgp. All assays were carried out in 50 mM Tris-Cl buffer, pH 7.5, and 37°C with 2 mM excess of MgSO 4 over ATP. Specific ATPase activities were determined at 3 mM MgATP (the highest technically feasible radioactive MgATP concentration). Verapamil (150 M) was added in dimethyl sulfoxide, and equivalent amounts of dimethyl sulfoxide were added in reactions that did not contain verapamil. [␣- 32 P]ATP Binding Experiments-5-10 g of protein that had been activated with DTT and E. coli lipids as above was incubated at 37°C for 20 min with Mg-[␣-
Incubation of Pgp with Nucleotide in Binding Experiments
32 P]ATP (concentrations as described in figure legends) in 40 mM Tris-HCl, pH 7.4, 0.1 mM EGTA, 2.0 mM MgSO 4 , in a total volume of 50 l. When present, the verapamil concentration was 150 M, and the V i concentration was 200 M. Next, samples were placed on ice, and 50 l of ice-cold buffer was added, then the whole 100 l was immediately passed through a centrifuge column as above.
[ [8] [9] [10] [11] [12] [13] [14] C]ADP Binding Experiments-The same procedure was followed except the incubation was for 120 min at 37°C. Previous experiments had indicated that the longer time is needed to attain saturation with ADP in the presence of V i (22) .
Thin Layer Chromatography of Centrifuge Column Eluates
For determination of radioactive ATP and ADP in centrifuge column eluates, samples were collected directly into tubes containing 100 l of 1 M HCOOH, 0.5 M LiCl at 4°C. After thorough mixing, 5-10 l was spotted onto polyethyleneimine-cellulose F plates (EM Science; Gibbstown, NJ) and developed with 1 M HCOOH, 0.5 M LiCl solution. Amounts of radioactive ATP and ADP were quantitated using a PhosphorImager (Molecular Dynamics).
RESULTS
General-The purpose of this work was to characterize the conformation of mouse MDR3 Pgp that is generated by combined mutation of both catalytic carboxylate residues, namely Glu-552 and Glu-1197, situated in the two NBDs. We constructed the double mutants E552Q/E1197Q, E552A/E1197A, E552D/E1197D, and E552K/E1197K, in which the mutations are predicted to produce a variety of environmental changes, namely removal of the carboxyl charge with minimal steric effect (Gln), removal of the side chain (Ala), shortening of the side chain with retention of the carboxyl (Asp), and insertion of a positive rather than negative charge (Lys). We used purified protein activated with lipids and DTT (8) and the natural ligands ATP and ADP to characterize the mutant proteins. Mutant proteins were expressed and purified from fermentergrown P. pastoris cells, as described previously (8, 21) . They displayed a single band when 5-10 g was run on SDS-gels (not shown) and were obtained in yields equal to or slightly higher than wild-type Pgp.
ATPase Activity of Mutant Proteins-It was apparent from preliminary experiments that ATPase activity of the pure mutant proteins was very low compared with wild-type. Sensitive assays were therefore conducted using radioactive [␥-
32 P]ATP as described previously (31) . Fig. 1 shows data for each of the mutants. It is evident that the activity was so low as to be close to the detection limit of the assay. Specific activities (V) are given in the figure, and for comparison it may be noted that wild-type specific activity in the presence of 150 M verapamil was 2.2 mol/min/mg in this assay (the highest ATP concentration that can be used is 3 mM). Thus the impairment in the mutants was by 425-fold (Ala) up to 1,000-fold (Lys). Whereas wild-type activity was accelerated by verapamil by around 10-fold, activity of the mutant proteins was the same whether verapamil was present or absent (not shown).
The low ATPase activities seen in Fig. 1 might conceivably be referable, wholly or partly, to contaminating proteins in the purified Pgp preparations. However, we consistently found good agreement between duplicate preparations of the same mutant Pgp. In addition, another purified mutant Pgp species (E552A/S528A) showed close to zero ATPase (V Յ 0.0008 mol/ min/mg), 4 again with excellent agreement between duplicate preparations. Therefore, although interference from contaminating ATPases cannot be completely ruled out, the differences between the mutant Pgp species in Fig. 1 ions) then passed through a centrifuge column to remove unbound ligand, no radioactive nucleotide elutes with the protein, showing that the dissociation rate of the nucleotide is sufficiently fast that none is retained on the protein (see "Discussion"). However, upon preincubation of wild-type Pgp with MgATP or MgADP and V i anion, followed by centrifuge column elution, radioactive nucleotide becomes tenaciously "trapped" in the catalytic sites at a stoichiometry of 1 mol/mol Pgp and is released only very slowly (11, 17) . 2B shows thin layer chromatography (TLC) of the eluates to identify the nucleotide species (ATP or ADP) that was retained.
Confirming previous work, wild-type Pgp did not retain any radioactive nucleotide after centrifuge column elution when preincubated in the absence of V i . However, if V i were present in the preincubation, radioactive nucleotide was retained to the extent of 1 mol/mol in the presence of verapamil, and to lesser extent (under the conditions chosen) in the absence of verapamil. As seen in Fig. 2B , with wild-type Pgp all of the retained nucleotide was in the form of ADP, consistent with previous work (17, 33). The mutant proteins showed behavior different both from wild-type and from each other. First, looking at the E552A/E1197A protein, it is seen from Fig. 2A that it retained the same amounts of radioactive nucleotide (ϳ1 mol/mol in the presence of verapamil) whether V i was present or absent in the preincubation. Fig. 2B shows that the majority (ϳ80%) of the retained nucleotide was in the form of ATP, consistent with the very low turnover rate for hydrolysis seen in Fig. 1 . Thus, this mutant has gained the ability to bind ATP tightly. Inclusion of V i made little difference to the proportion of ATP versus ADP retained, showing that "vanadate trapping" was not occurring in the mutant. Fig. 2A indicates that verapamil still increased the binding of nucleotide, showing that signal transmission between drug binding sites and nucleotide binding sites was not lost. The E552Q/E1197Q mutant also showed V i -independent binding of nucleotide ( Fig. 2A) . The stoichiometry of retained nucleotide was lower (ϳ0.5 mol/mol Pgp) than in the case of the Ala mutant. There was an effect of verapamil to increase the amount of nucleotide bound, and as Fig. 2B shows, the retained nucleotide was ϳ60% ATP and ϳ40% ADP, again consistent with the very slow hydrolytic turnover rate seen in Fig. 1 . It may be noted that the presence of more bound ATP than ADP in the E552A/E1197A and E552A/E1197A mutants (Fig. 2B) indicates that ADP release per se is not rate limiting for ATPase turnover and is not the cause of inhibition. The E552D/ E1197D mutant retained low amounts of nucleotide (ϳ0.1 mol/ mol), and the E552K/E1197K mutant retained none ( Fig. 2A) .
Characterization of the ATP Binding Properties of the E552A/ E1197A and E552Q/E1197Q Mutant Pgp-We found that if the experiments of Fig. 2A Fig. 3 . Calculated K d values were: E552A/E1197A, 9.2 M; E552Q/E1197Q, 38 M. It may be noted that a better fit was obtained with both mutants when the Hill equation was used to fit the data rather than a simple single-site equation. Hill coefficients for the best fits were: E552A/E1197A, n ϭ 1.6; E552Q/E1197Q, n ϭ 1.4. It was also notable that the curves saturated at stoichiometry values substantially lower than 2 mol/mol. Incubation for longer times did not increase the stoichiometry of ATP bound. The binding curves in Fig. 3 were performed in the absence of V i ; very similar curves and K d values were seen in the presence of V i .
The centrifuge column technique used in Figs. 2A and 3 is convenient in that it uses low amounts of Pgp and is rapid, however it is not a true equilibrium binding method. We suspected that a fast dissociation rate of MgATP might explain the low binding stoichiometries seen with some of the mutants, and this was studied in Fig. 4A . In this experiment, Pgp was preincubated with Mg[␣- 32 P]ATP and then eluted through a first centrifuge column as in Fig. 2A . The eluate was then incubated for different periods of time before being passed through a second centrifuge column, and nucleotide still retained was determined. Data with wild-type Pgp preincubated with V i and MgATP were included as a control, and gave a t1 ⁄2 for release of V i -trapped nucleotide of 70 min (Fig. 4A) , consistent with previous results (21, 31) . The mutants were preincubated without V i , and the calculated t1 ⁄2 values and dissociation rates were as follows: E552A/E1197A, 17.6 min, k ϭ 6.6 ϫ 10 Ϫ4 s Ϫ1 ; E552Q/ E1197Q, 2.5 min, k ϭ 4.6 ϫ 10 Ϫ3 s Ϫ1 . The same results were obtained if V i was present in the preincubation. The faster rate of nucleotide dissociation from the E552Q/E1197Q versus the E552A/E1197A mutant explains the lower stoichiometry of nucleotide retained after the centrifuge column elution in Figs. 2A  and 3 . It is reasonable to extrapolate that the E552D/E1197D and E552K/E1197K mutants retain less nucleotide ( Fig. 2A) because they have still faster dissociation rates.
Rates of binding of MgATP to the E552A/E1197A mutant were compared in the presence and absence of V i and at different temperatures (Fig. 4B) . It is seen that V i had little effect on the rate of association at 37°C and had a slight accelerating effect at 23°C. There was a large difference in apparent rate of binding at 37°C (t1 ⁄2 ϭ 3.0 min) compared with 23°C (t1 ⁄2 ϳ100 min). Fig. 5 shows experiments in which wild-type and mutant Pgp were preincubated with [8- 14 C]ADP in the presence or absence of V i and/or verapamil, then passed through centrifuge columns to determine the amount of retained ADP. The results with wild-type Pgp mirrored those published previously (22) , showing a dependence on V i for retention of ADP and a strong effect of verapamil to increase the amount of ADP retained. Stoichiometry of V i -trapped ADP in wild-type was around 1 mol/mol Pgp. E552A/E1197A mutant Pgp showed binding and retention of ADP which was also verapamil-sensitive but was V i -independent. Maximal stoichiometry of bound ADP in the presence of verapamil was around 1 mol/mol Pgp in the presence or absence of V i . E552Q/E1197Q Pgp retained less ADP (Fig. 5) , but the small amount retained was again V i -independent and verapamil-sensitive. Longer incubation times did not increase the stoichiometry of retained ADP. The E552D/E1197D and E552K/E1197K mutants retained very little ADP.
Characterization of the ADP Binding Properties of the E552A/E1197A and E552Q/E1197Q Mutant Pgp-
The K d for ADP binding was determined by preincubating Pgp with varying concentrations of [8- 14 C]ADP and then passing it through centrifuge columns to determine bound nucleotide. Fig. 6A shows the data for the E552A/E1197A mutant, yielding a calculated K d value of 92 M. The solid line shows a fit to the Hill equation with n ϭ 1.7. The dotted line is a fit to a model with a single site. Binding of ADP was seen to be Mg 2ϩ -dependent and Na ϩ -independent, as with ATP. Given the low amounts of ADP bound to the other three mutants in Fig. 5 , we did not attempt to determine K d values for any of them. The dissociation rate of bound [8- 14 C]ADP from the E552A/E1197A mutant was measured directly in Fig. 6B , and the t1 ⁄2 was 18.7 min (k ϭ 6.2 ϫ 10 Ϫ4 s Ϫ1 ) i.e. essentially the same as for ATP dissociation (above). Dissociation rates for the other mutants were not measured, but it is reasonable to assume from Fig. 5 that the lowered stoichiometry of retained ADP is because of faster dissociation, in the order Lys Ͼ Asp Ͼ Gln Ͼ Ala, similar to the pattern with ATP.
DISCUSSION
The work of Sauna et al. (28) had shown that combined mutation of the two catalytic carboxylate Glu residues that lie adjacent to the Walker B Asp residue in the NBDs of human P-glycoprotein (to Gln or Ala) generated a conformation of Pgp which had lost ATPase activity and gained the ability to bind nucleotide tightly. Here we initially confirmed that observation, then we characterized the new conformation using pure MDR3 mouse Pgp, studying in detail binding parameters for the natural ATP and ADP. We generated mutants with Ala, Gln, Asp, and Lys substitutions at residues Glu-552 and Glu-1197 (i.e. E552A/E1197A, etc.), producing a range of effects. Fig. 1 showed that the ATPase activity of the mutants was not zero, although it was certainly very low. The order of retention of residual activity in the mutants was Ala Ͼ Gln Ͼ Asp Ͼ Lys, and the reduction ranged from 425-fold (Ala) to 1,000-fold (Lys). The data confirm the now widely established notion that this conserved Glu residue is critical for ATP hydrolysis in Pgp and ABC transporters (see the Introduction). It is of interest that even mutation to Asp, not previously studied in Pgp, was just as detrimental as Ala or Gln, demonstrating an exquisitely sensitive stereochemical requirement for the Glu carboxyl side chain.
Studies of [␣-32 P]ATP binding revealed how different the mutants were from wild-type. Normally native wild-type Pgp does not retain any nucleotide in an experiment where centrifuge column elution is used to separate bound from free ligand after preincubation of Pgp with MgATP. K m MgATP is in the 0.3-1 mM range as published by many different laboratories, and measurements of MgATP binding using a fluorescently (35) reported that under the conditions of centrifuge column elution used here, the protein transit time is ϳ30 s, implying that a ligand would have to dissociate with k Յ 0.006 s Ϫ1 for Ն90% to be retained. However, if V i is included in the preincubation of Pgp with MgATP, then ADP becomes tenaciously trapped with a stoichiometry of 1 mol/mol Pgp and dissociation rate of 1.4 ϫ 10 Ϫ4 s Ϫ1 at 37°C (17). Under these conditions, still no ATP is retained by wild-type Pgp. The Pgp⅐MgADP⅐V i species is thought to mimic a chemical transition state of the ATP hydrolysis reaction, based on the criterion that it is expected to have trigonal bipyramidal geometry around the pentacovalent V atom, with the ADP-O to V bond lengthened with respect to the ADP-O to P bond in ATP, and with the equatorial oxygens planar rather than tetrahedral. Such an arrangement has been demonstrated for a natural transphosphorylation reaction (36) and was substantiated in the myosin⅐MgADP⅐V i complex (37) by x-ray crystallography.
In contrast to wild-type Pgp, both the E552A/E1197A and E552Q/E1197Q mutants retained nucleotide after preincubation with [␣-
32 P]ATP in the absence of V i . Moreover, V i had no effect on the stoichiometry of nucleotide binding, the rate of nucleotide release, the calculated K d , or the association rate. Similarly, the stoichiometry of [8- 14 C]ADP binding was not affected by V i . Therefore we can conclude that these mutants, although binding the nucleotide tightly, do not form a transition state-like complex with V i comparable with that seen in wild-type. This indicates that the Glu-552 and Glu-1197 residues acting together are involved in bond formation at the transition state. A similar situation was shown for the catalytic Glu carboxylate in F 1 -ATPase, using ADP-fluoroaluminate as the transition state trapping agent (38) . The tightly bound nucleotide-Pgp complex cannot be considered as a transition state merely on the basis of its slow dissociation rate. Rather, the mutants reveal a conformation of Pgp in which bound nucleotide per se has become occluded.
Direct analysis by TLC of the nucleotide retained by the E552A/E1197A and E552Q/E1197Q mutants after preincubation with [␣-32 P]ATP showed that both ATP and ADP were present. 5 This finding is not unexpected, given that both enzymes are capable of slow ATP hydrolysis (Fig. 1) . Because of the slow turnover rate we were not able to measure K m MgATP in the mutant enzymes accurately, but if one assumes it is the same as in wild-type (0.34 mM, Ref. 31) , then during the preincubation phase of the experiment shown in Fig. 2 , approximately four turnovers would have occurred on each enzyme molecule on average. In the E552A/E1197A mutant, where 80% of the bound nucleotide was ATP, the measured K d and association/dissociation rate constants will faithfully represent values for MgATP. It was found that the K d for MgATP was 10-fold lower than for MgADP. The dissociation rates for MgATP and MgADP were the same. Thus we conclude that in E552A/E1197A mutant we are seeing a conformation of Pgp which binds ATP tightly and preferentially, hydrolyzes it very slowly, and subsequently releases MgADP slowly.
Results with the E552Q/E1197Q mutant showed a similar but not identical pattern. After preincubation with [␣-32 P]ATP 5 Sauna et al. (28) concluded that after incubation of the analogous human Pgp mutants with 8-azido-ATP, only 8-azido-ADP was bound. This conclusion was not based on direct analysis of the bound nucleotide, rather it was inferred from experiments comparing labeling after incubation with 8-azido-[␣- Preincubation of the mutant protein was as in Fig. 5 with verapamil present and vanadate absent. After passage of samples through a first centrifuge column to remove unbound ligand the eluates were incubated further for varying times at 37°C, then passed through a second centrifuge column, and nucleotide retained on the protein was determined. Each point represents the mean of at least triplicates in this figure. followed by centrifuge column elution, ATP and ADP were retained in approximately equal proportion. Release of bound nucleotide was clearly slow compared with wild-type, and comparison of Figs. 2 and 5 suggests that ADP release is faster than ATP release. The measured K d for nucleotide binding to this mutant in Fig. 3 is ambiguous (because both MgATP and MgADP are bound), but the data serve to prove that an occluded nucleotide binding conformation is present. Nevertheless, it is also clear that this mutant retained nucleotide less effectively than E552A/E1197A. This trend was continued with the E552D/E1197D and E552K/E1197K mutants. It is evident that the mutants formed a series, with ability to occlude nucleotide in the order Ala Ͼ Gln Ͼ Asp Ͼ Lys.
The same series was seen for ATP hydrolysis activity (above), underscoring that although release of MgADP product is much slower in these mutants than in wild-type, impaired release of MgADP per se is not the primary cause of reduced ATPase turnover. If this were so, the Lys and Asp mutants should have the higher activity. We conclude therefore that a direct impairment of the hydrolysis step is the primary cause of low ATPase activity. This is also supported by the finding in Fig. 2B that in E552A/E1197A and E552Q/E1197Q bound ATP was preponderant over bound ADP after preincubation with MgATP.
It is tempting to conclude that the occluded state correlates with dimerization of the Pgp NBDs. As discussed in the Introduction there is strong indication from work on other ABC transporters that the mutations introduced here (particularly Glu to Gln) promote formation and stability of an NBD dimer structure which occludes nucleotide. Assuming that such a structure does occur in Pgp, our interpretation of the effects of the mutations on Pgp is as follows. In wild-type, ATP binding to two NBDs together with occupation of the drug binding site(s) induces dimerization, which is followed rapidly by transition state formation at one of NBDs, generating ADP, which leaves as the NBD dimer dissociates (22) . In the Ala mutant where the Glu side chain is removed, ATP binding occurs, dimerization follows, but as hydrolysis is prevented because the transition state is relatively inaccessible, the enzyme is largely arrested in the dimer form. The temperature dependence of nucleotide occlusion (Fig. 4B) is supportive of this. In the Gln mutant where the side chain stereochemistry is similar to wild-type a similar explanation is possible, but with the occluded dimer state being less stable. In the Lys mutant, introduction of a positive charge disrupts dimer stability either through disruption of protein-protein interaction or through impairment of ATP binding (ATP appears to be an important structural component at the dimer interface; Refs. 29 and 30). The Asp mutant is more difficult to interpret; perhaps it represents a combination of these effects.
It must be stressed, however, that direct high resolution structural evidence linking NBD dimer formation to the catalytic pathway is so far lacking for Pgp. Thus the foregoing discussion remains speculative. This is an important area for future studies. The E552A/E1197A mutant, which appears to produce the most stable occluded state, may well facilitate structural studies of Pgp.
It is important to discuss the stoichiometry of bound nucleotide seen in our experiments in relation to what might have been predicted from previous work on Pgp and what has been found with other ABC transporters. There is ample evidence from previous work that both NBDs in Pgp are catalytic sites, as discussed in the Introduction. Recent work using fluorescence titrations showed direct binding of two nucleoside di-or triphosphates/mol of wild-type Pgp (34) . On this basis one might have expected the maximal stoichiometry of bound nucleotide in mutants such as E552A/E1197A to have been 2 mol/mol rather than the 1 mol/mol actually found. It is germane that the binding curves for MgATP and MgADP were well fit by the Hill equation with n Ͼ 1, implying cooperativity between both NBDs in the binding event. Thus the E552A/ E1197A mutant, although it apparently was capable of binding MgATP or MgADP at both sites, still showed asymmetry in that occlusion of nucleotide occurred at only one site with the other nucleotide presumably lost during the centrifuge column elution. This is redolent of previous work in which formation of the inhibited Pgp⅐MgADP⅐V i complex from wild-type Pgp and V i , plotted as a function of MgADP or MgATP concentration, also showed cooperativity (22) , indicating nucleotide binding at two sites occurs initially, yet only 1 mol of MgADP becomes trapped by V i per mol of Pgp as measured by centrifuge column elution. It may also be mentioned that Sauna et al. (28) found by UV-photolabeling and trypsin hydrolysis that the 8-azido-ADP occluded by the E556Q/E1201Q mutant of human Pgp after preincubation with 8-azido-ATP was distributed about equally in N-and C-halves of the protein, implying binding in both NBDs (the stoichiometry of bound nucleotide was not determined).
In x-ray structures of isolated NBDs in dimeric form from other ABC transporters, two ATP are seen bound at the dimer interface (29, 30) , and the NBDs appear symmetrical. In the Mdl1p ABC transporter, the stoichiometry of the nucleotide retained by the dimeric isolated NBD containing the catalytic Glu to Gln mutation after preincubation with ATP (Ϯ Mg 2ϩ ) and gel filtration was 2.2-2.5 mol/mol (26) . Dimer formation was ATP-dependent. If the preincubation was in the absence of Mg 2ϩ then all of the bound nucleotide was in the form of ATP. If Mg 2ϩ was present during preincubation and the ATP concentration was low, then both ATP and ADP, in equal amount, were bound to dimers (as in the case of Pgp, the Mdl1p Glu to Gln mutant showed a very low but real ATP hydrolysis). However, at higher ATP concentrations in the presence of Mg 2ϩ , all of the nucleotide was ATP, suggesting that ADP dissociation from the dimer was faster than that of ATP and that ATP was able to fill an empty site rapidly. Thus some functional asymmetry was apparent. The intact Bacillus subtilis ABC transporter BmrA was studied in Ref. 27 after purification and reconstitution in proteoliposomes. Wild-type protein behaved much like wild-type Pgp in that it retained nucleotide only after preincubation with both V i and 8-azido-ATP, in an Mg 2ϩ -dependent manner, at a stoichiometry of 1 mol/mol, with all of the retained nucleotide in the form of 8-azido-ADP. Mutations of the catalytic Glu in both NBDs reduced basal ATPase activity to a very low level. Binding of 8-azido-ATP in the mutants was found to be V i -independent, Mg-dependent, and temperature-sensitive. Stoichiometry of bound 8-azido-ATP after washing by ultracentrifugation to remove unbound ligand was 1 mol of 8-azido-ATP/mol of dimer with apparently no 8-azido-ADP bound. Thus the intact BmrA mutants behaved somewhat like the Pgp mutants described here, retaining up to 1 mol of nucleotide/mol of protein, i.e. there was distinct functional asymmetry in the NBDs.
Of course it is possible that not all ABC transporters will necessarily follow the same exact mechanism. Still it is tempting to speculate that in intact transporters the NBD dimer has a greater tendency to move to a transient asymmetric state after the initial filling of two sites by ATP, leading to transition state formation, catalysis, and release of product. This may be reflected in the fact that ATPase activity in intact transporters is usually high compared with that of isolated NBDs. NBD asymmetry may explain at least in part why the mutant Pgp and BmrA only retained 1 mol of nucleotide/mol despite being in an occluded state. Obviously, more information will be needed to understand this aspect.
In conclusion, the results presented here show that combined mutation of the catalytic carboxylate Glu residues in both NBDs of Pgp promotes formation of an occluded conformation in which nucleotide is bound tightly, contrasting with wildtype. Both ATP and ADP are occluded. ATPase activity is reduced to a low but real residual turnover rate, caused primarily by a change in bond formation at the transition state rather than by slowed release of ADP product. The data are discussed in relation to possible dimerization of Pgp NBDs, its involvement in catalytic mechanism, and stabilization of this state to different degrees by different mutations. The E552A/ E1197A mutant is particularly likely to be valuable for structural studies of Pgp.
